FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 355:1949-1952 November 9, 2006 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

In September, at the World Cardiology Congress in Barcelona, Donald Baim, a cardiologist who is the new chief medical and scientific officer of Boston Scientific, was talking to a reporter when he mentioned disturbing new findings regarding the risk of late thrombosis associated with drug-eluting coronary stents. The revelation fueled a newly ignited controversy. Lauded as a means of preventing restenosis, drug-eluting stents have been implanted in nearly 6 million patients worldwide since they were introduced 3 years ago. The Food and Drug Administration (FDA) responded to the controversy by issuing a statement that drug-eluting stents are "safe and effective . . . [Full Text of this Article]

Source Information

Dr. Shuchman is an assistant professor in the Department of Psychiatry at the University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY.

This article has been cited by other articles:

• Park, D.-W., Yun, S.-C., Lee, S.-W., Kim, Y.-H., Lee, C. W., Hong, M.-K., Cheong, S.-S., Kim, J.-J., Park, S.-W., Park, S.-J. (2008). Stent Thrombosis, Clinical Events, and Influence of Prolonged Clopidogrel Use After Placement of Drug-Eluting Stent: Data From an Observational Cohort Study of Drug-Eluting Versus Bare-Metal Stents. J Am Coll Cardiol Intv 1: 494-503 [Abstract] [Full Text]  
• Malenka, D. J., Kaplan, A. V., Lucas, F. L., Sharp, S. M., Skinner, J. S. (2008). Outcomes Following Coronary Stenting in the Era of Bare-Metal vs the Era of Drug-Eluting Stents. JAMA 299: 2868-2876 [Abstract] [Full Text]  
• Kelbaek, H., Klovgaard, L., Helqvist, S., Lassen, J. F., Krusell, L. R., Engstrom, T., Botker, H. E., Jorgensen, E., Saunamaki, K., Aljabbari, S., Thayssen, P., Galloe, A., Jensen, G. V.H., Thuesen, L. (2008). Long-Term Outcome in Patients Treated With Sirolimus-Eluting Stents in Complex Coronary Artery Lesions: 3-Year Results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) Trial. J Am Coll Cardiol 51: 2011-2016 [Abstract] [Full Text]  
• Hannan, E. L., Racz, M., Holmes, D. R., Walford, G., Sharma, S., Katz, S., Jones, R. H., King, S. B. III (2008). Comparison of Coronary Artery Stenting Outcomes in the Eras Before and After the Introduction of Drug-Eluting Stents. Circulation 117: 2071-2078 [Abstract] [Full Text]  
• Hannan, E. L., Racz, M., Walford, G., Holmes, D. R., Jones, R. H., Sharma, S., Katz, S., King, S. B. III (2008). Drug-Eluting Versus Bare-Metal Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol Intv 1: 129-135 [Abstract] [Full Text]  
• Wacker, B. K., Alford, S. K., Scott, E. A., Das Thakur, M., Longmore, G. D., Elbert, D. L. (2008). Endothelial Cell Migration on RGD-Peptide-Containing PEG Hydrogels in the Presence of Sphingosine 1-Phosphate. Biophys. J 94: 273-285 [Abstract] [Full Text]  
• Tu, J. V., Bowen, J., Chiu, M., Ko, D. T., Austin, P. C., He, Y., Hopkins, R., Tarride, J.-E., Blackhouse, G., Lazzam, C., Cohen, E. A., Goeree, R. (2007). Effectiveness and Safety of Drug-Eluting Stents in Ontario. NEJM 357: 1393-1402 [Abstract] [Full Text]  
• Schomig, A., Dibra, A., Windecker, S., Mehilli, J., Suarez de Lezo, J., Kaiser, C., Park, S.-J., Goy, J.-J., Lee, J.-H., Di Lorenzo, E., Wu, J., Juni, P., Pfisterer, M. E., Meier, B., Kastrati, A. (2007). A Meta-Analysis of 16 Randomized Trials of Sirolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease. J Am Coll Cardiol 50: 1373-1380 [Abstract] [Full Text]  
• Daemen, J., Serruys, P. W. (2007). Drug-Eluting Stent Update 2007: Part II: Unsettled Issues. Circulation 116: 961-968 [Full Text]  
• Bode, C. (2007). Introduction. Eur Heart J Suppl 9: D1-D2 [Full Text]  
• Bode, C., Zehender, M. (2007). The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis. Eur Heart J Suppl 9: D10-D19 [Abstract] [Full Text]  
• Howard-Alpe, G. M., de Bono, J., Hudsmith, L., Orr, W. P., Foex, P., Sear, J. W. (2007). Coronary artery stents and non-cardiac surgery. Br J Anaesth 98: 560-574 [Abstract] [Full Text]  
• Kastrati, A., Mehilli, J., Pache, J., Kaiser, C., Valgimigli, M., Kelbaek, H., Menichelli, M., Sabate, M., Suttorp, M. J., Baumgart, D., Seyfarth, M., Pfisterer, M. E., Schomig, A. (2007). Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. NEJM 356: 1030-1039 [Abstract] [Full Text]  
• Rocca, H.-P. B.-L., Kaiser, C., Pfisterer, M., on behalf of the BASKET Investigators, (2007). Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET). Eur Heart J 28: 719-725 [Abstract] [Full Text]  
• Lang, N. N., Newby, D. E. (2007). Emerging Thrombotic Effects of Drug Eluting Stents. Arterioscler. Thromb. Vasc. Bio. 27: 261-262 [Full Text]  
• Shuchman, M. (2007). Debating the Risks of Drug-Eluting Stents. NEJM 356: 325-328 [Full Text]  
• Knudtson, M. L. (2007). Drug-eluting coronary stents: faith and hope, but no charity. CMAJ 176: 195-196 [Full Text]